Colimycin therapy for multiresistant Pseudomonas aeruginosa cholangitis;Utilisation de la colimycine pour le traitement d'angiocholites à Pseudomonas aeruginosa multirésistants

Medecine et Maladies Infectieuses

Volumn 42, Issue 8, 2012, Pages 366-369

  N'Guyen, Y ^a,b   Hentzien, M ^a   Goehringer, F ^a,c   Vernet Garnier, V ^a   Strady, C ^a,b,d  

^a SERVICE DE DERMATOLOGIE   (France)

^b University of Reims Champagne Ardenne   (France)

^c CHU NANCY BRABOIS   (France)

^d Groupe Courlancy   (France)

Author keywords

Colimycin; Multi drug resistance; Pseudomonas aeruginosa

Indexed keywords

COLISTIN;

ANTIBIOTIC THERAPY; ARTICLE; CHOLANGITIS; DRUG UTILIZATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

AGED; ANTI-BACTERIAL AGENTS; CHOLANGITIS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84864626194     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2012.06.002     Document Type: Article

References (10)

1. Barbier F., Wolff M. Multirésistance chez Pseudomonas aeruginosa: vers l'impasse thérapeutique ?. Med Sci (Paris) 2010, 26:960-968.
2. European antimicrobial resistance surveillance system-EARSS annual report 2008. (accedé le 29 mars 2012). http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2008_EARSS_Annual_Report.pdf.
3. Sanchez A., Gattarello S., Rello J. New treatment options for infections caused by multiresistant strains of Pseudomonas aeruginosa and other non fermenting Gram negative bacilli. Semin Respir Crit Care Med 2011, 32:151-158.
4. Gobin P., Lemaître F., Marchad S., Couet W., Olivier J.C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010, 54:1941-1948.
5. Struelens M.J., Rost F., Deplano A., Maas A., Schwam V., Serruys E., et al. Pseudomonas aeruginosa and Enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. Am J Med 1993, 95:489-498.
6. Bert F., Lambert-Zechovsky N. Antibiotic resistance patterns in Pseudomonas aeruginosa: an 8-year surveillance study in a French hospital. Int J Antimicrob Agents 1997, 9:107-112.
7. Lang B.J., Aaron S.D., Ferris W., Hebert P.C., Mc Donald M.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000, 162:2241-2245.
8. Haute Autorité de santé. Avis de la commission de transparence du 26 novembre 2008. (consulté le 29 mars 2012). http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-12/colimycine_-_ct-4947.pdf.
9. Dudhani R.V., Turnidge J.D., Coulthard K., Milne R.W., Rayner C.R., Li J., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010, 54:1117-1124.
10. Dalfino L., Puntillo F., Mosca A., Monno R., Spada M.L., Copolecchia S., et al. High dose extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-1726.